Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Double-dummy, Multicenter, Adaptive Design, Dose Escalation (Part 1) and Dose-Response (Part 2) Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery

Trial Profile

A Randomized, Double-blind, Double-dummy, Multicenter, Adaptive Design, Dose Escalation (Part 1) and Dose-Response (Part 2) Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ichorcumab (Primary) ; Apixaban
  • Indications Venous thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TEXT-TKR
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 16 Sep 2019 Results (n=239) safety and efficacy of JNJ-9375 with apixban in prevention of venous thrombosis, published in the Journal of Thrombosis and Haemostasis.
    • 18 Mar 2019 Results presented at the 68th Annual Scientific Session of the American College of Cardiology
    • 06 Feb 2019 The trial has been Discontinued in Greece, according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top